Company

Company

Who we are

MRM Proteomics Inc. is a provider of high quality technologies for proteomics.

MRM Proteomics Inc. was originally launched in 2010 as a spin-off company to commercialize the cutting-edge proteomics technologies, tools, and know-how developed at the University of Victoria-Genome BC Proteomics Centre.

Since then, MRM Proteomics Inc. has opened independent laboratories in Victoria and Montreal, provided proteomics services to many clients, established its own in-house technology development program, and developed and launched new commercial products.

MANAGEMENT TEAM

CLAUDE LEDUC

President & Chief Executive Officer

Claude LeDuc is a professional executive with 30 years of international experience and achievement in private and Fortune 500 Pharma, Biotech and Medical Devices Companies…

CHRISTOPH H.
BORCHERS, PhD

Chief Scientific Officer

Dr. Christoph Borchers is recognized as a pioneer and leading figure in the development of mass spec based methods for protein quantification using Multiple Reaction Monitoring…

GERALD BATIST, MD, FACP

Chief Medical Officer

Dr. Gerald Batist is Deputy Director and Senior Investigator at the Lady Davis Institute and a Fellow of the Canadian Academy of Health Sciences…

BOARD OF DIRECTORS

GABE KALMAR, PhD

Chair

Dr. Kalmar is currently Vice President, Sector Development for Genome British Columbia….

BRENT STERNIG, MBA

Director

Mr. Sternig is the Director of Research Partnerships and Knowledge Mobili-
zation at the University of Victoria…

JENNIFER
KAUFMAN-SHAW, PhD, LLB

Director

Dr. Kaufman-Shaw is currently Vice President, Legal Affairs and Intellectual Property at ImStar Therapeutics Inc….

CLAUDE LEDUC

President & Chief Executive Officer

Claude LeDuc is a professional executive with 30 years of international experience and achievement in private and Fortune 500 Pharma, Biotech and Medical Devices Companies…

CHRISTOPH H.
BORCHERS, PhD

Chief Scientific Officer

Dr. Christoph Borchers is recognized as a pioneer and leading figure in the development of mass spec based methods for protein quantification using Multiple Reaction Monitoring…

Claude Leduc

CLAUDE LEDUC

President & Chief Executive Officer

Claude LeDuc is a professional executive with 30 years of international experience and achievement in private and Fortune 500 Pharma, Biotech and Medical Devices Companies. As a CEO/COO, Mr. Leduc financially structured companies through seeds and multiple rounds of financing, with successfully realized IPO and private investments of tens of millions of dollars. He has also built teams and structures to execute clinical trials, manufacturing needs, QA/QC and regulatory approval requirements. Mr. LeDuc prepared companies for their pre-commercialization phase, managed negotiations with worldwide partners, and secured commercial partnerships. His sales and marketing background and international business development experience gives him tremendous vision to translating novel technologies into viable businesses.

Claude Leduc

CHRISTOPH H. BORCHERS, PhD

Chief Scientific Officer

Dr. Christoph Borchers is recognized as a pioneer and leading figure in the development of mass spec based methods for protein quantification using Multiple Reaction Monitoring (MRM). He is also the Director of the UVic–Genome BC Proteomics Centre and has published more than 180 peer-reviewed papers in scientific journals. His research is centered around the improvement, development and application of proteomics technologies with a major focus on techniques for quantitative targeted proteomics for clinical diagnostics. Dr. Borchers received his B.S., M.Sc. and Ph.D. from the University of Konstanz, Germany. After his post-doctoral training and employment as a staff scientist at NIEHS/NIH/RTP, NC and he was the director of the Duke–UNC Proteomics Facility and held a faculty position at UNC Medical School in Chapel Hill, NC (2001-2006). Dr. Borchers is also involved in promoting proteomics research and education through his involvement with HUPO (International Council Member), the British Columbia Proteomics Network (co-leader) and the Canadian National Proteomics Network (VP External, Chair of the Board of Directors).

GERALD BATIST, MD, FACP

Chief Medical Officer

Dr. Gerald Batist is Deputy Director and Senior Investigator at the Lady Davis Institute and a Fellow of the Canadian Academy of Health Sciences. As an international leader in cancer therapy research, he is known for his innovative work in molecular oncology and precision medicine. He has generated leading edge experimental data on mechanisms of tumour resistance and strategies to overcome it. His laboratory and clinical research program has been credited with over 180 scientific publications. He has trained many scientists and clinical oncologists, and also practices medical oncology.
Dr. Batist holds several additional directorships including Director of the McGill Centre for Translational Research in Cancer at the Lady Davis Institute, Director of the Segal Cancer Centre at Jewish General Hospital, Director of the Department of Oncology at Sir Mortimer B. Davis-Jewish General Hospital, and Scientific Director of the Montreal Centre for Experimental Therapeutics in Cancer. He helps lead the National Centre of Excellence in Personalized Medicine called Exactis. He is also a professor in the Department of Medicine and Minda de Gunzburg Professor of Oncology at McGill University.
Dr. Batist founded the McGill Centre for Translational Research in Cancer, the research core of the Segal Cancer Centre at the Jewish General Hospital, which is focused on efficient translation of new research discoveries into clinical benefits for patients. He also created the Quebec Consortium for Clinical Research in Cancer (Q-CROC). Q-CROC operates as a network for oncology care and research, with a focus on biomarker-driven clinical trials and conducting serial biopsies of metastatic cancers that will define molecular signatures of therapeutic resistance to specific treatments.

Claude Leduc

BRENT STERNIG, MBA

Director

Mr. Sternig is the Director of Research Partnerships and Knowledge Mobilization (RPKM) at the University of Victoria. He has over 18 years of experience in the areas of business development, intellectual property protection, technology licensing and new enterprise development. Mr. Sternig manages a portfolio of over 100 patents and has been involved with the creation and governance of over a dozen spin-off companies. He sits on the advisory council for NSERC Pacific’s regional operation and for UVic’s Innovation Centre for Entrepreneurs. He is a board member for Research Impact and is an active member of the Licensing Executives Society and Association of University Technology Managers. Mr. Sternig earned his Masters of Business Administration from Royal Roads University and his Diploma of Marketing Management from the British Columbia Institute of Technology.

Claude Leduc

GABE KALMAR, PhD

Chair

Dr. Kalmar is currently Vice President, Sector Development for Genome British Columbia. Previously he was engaged in strategic consulting activities with several early stage pharmaceutical companies which included overseeing operations, implementing technology development and providing merger and acquisition planning. From 1996 to 2002 Dr. Kalmar held senior management positions with Kinetek Pharmaceuticals Inc., a privately held Vancouver-based biopharmaceutical company that was acquired by QLT in March, 2004. During this time Dr. Kalmar established and managed multiple external collaborations with academics and clinicians in the areas of signal transduction, preclinical studies and technology access. Dr. Kalmar obtained his undergraduate science degree from the University of British Columbia and his PhD in Biology from Simon Fraser University.

Claude Leduc

JENNIFER KAUFMAN-SHAW, PhD, LLB

Director

Dr. Kaufman-Shaw is currently Vice President, Legal Affairs and Intellectual Property at ImStar Therapeutics Inc., a Vancouver-based company founded in 2012 to develop therapeutics for treating amyotrophic lateral sclerosis (ALS). She has over 20 years of legal experience in a biotechnology setting. From 2007 to 2012 Dr. Kaufman-Shaw was Vice President, Intellectual Property at Sirius Genomics Inc. For the 10 years prior to that she led the intellectual property department at QLT Inc., where she was responsible for the strategic management of the patent portfolios for the FDA-approved products PHOTOFRIN, VISUDYNE, ELIGARD and ACZONE as well as various patent litigation matters. Dr. Kaufman-Shaw has participated in numerous licensing, acquisition, joint development and financing transactions. Prior to becoming in-house counsel, she practiced law in the technology group of an Edmonton law firm, concentrating on intellectual property and life sciences. Dr. Kaufman-Shaw obtained both her PhD in biochemistry and her LL.B. from the University of Alberta. She became a registered patent agent in 1997.

Quick Contact

1 + 11 =

xx

LET US
HELP YOU